The 11 most recent market catalysts affecting $CELC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
JP Morgan analyst Anupam Rama initiated coverage on Celcuity (CELC) with an Overweight rating and a price target of $157. This event is significant for Celcuity as it marks the for…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 85
Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
Celcuity Inc. announced the submission of its supplemental New Drug Application (sNDA) to the FDA for REVTORPYK (gedatolisib). This sNDA is for the treatment of patients with HR+, …
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
Guggenheim analyst Brad Canino maintained a 'Buy' rating on Celcuity and raised the price target from $165 to $175. This action signals increased confidence from a prominent financ…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Celcuity, Maintains $155 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Celcuity (CELC) and maintained a $155 price target. This action s…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 75
Celcuity shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
This headline signals a strong positive corporate catalyst for Celcuity. Better-than-expected earnings often lead to immediate stock price appreciation as investors re-evaluate the…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 75
Celcuity Analysts Slash Their Forecasts After Q2 Loss
Celcuity (CELC) announced a Q2 loss that was better than analyst expectations, alongside significant clinical and regulatory progress for its drug gedatolisib (REVTORPYK). The CEO …
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
Needham Maintains Buy on Celcuity, Lowers Price Target to $140
Needham analyst Gil Blum maintained a 'Buy' rating on Celcuity but lowered the price target from $157 to $140. This adjustment signals a revised valuation by the analyst, likely du…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 75
Celcuity Q2 Adj. EPS $(1.07) Beats $(1.17) Estimate
Celcuity (CELC) announced its Q2 adjusted EPS loss of $(1.07), which was better than the consensus estimate of $(1.17). This beat could provide a short-term positive sentiment for …
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 85
Celcuity shares are trading lower after the company delayed the commercial launch of its newly approved breast cancer drug.
The delayed commercial launch of a newly approved drug is a major negative catalyst for a biotechnology company like Celcuity. This directly impacts the company's projected revenue…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177
Citizens analyst Silvan Turkcan has raised the price target for Celcuity (CELC) from $160 to $177 while maintaining a 'Market Outperform' rating. This action signals a strengthened…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on Celcuity and raised the price target from $145 to $155. This action signals continued confidence fro…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.